Savara schedules CHEST 2026 presentations for Savara stock

Published on 10/18/2026 at 13:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The November 22 FDA decision on MOLBREEVI sets the next test for Savara stock. Q3 2026 results are estimated for November 11 after the close.

Clinical and financial milestones

Savara announced its CHEST 2026 presentations on October 12, 2026.
Second-quarter 2026 earnings per share were USD -0.16 versus USD -0.14 expected.
Savara stock was last quoted at EUR 3.94 in Frankfurt on October 16, 2026.

SVRA, US8051111016, Illustration mit AI erstellt.

Savara (ISIN US8051111016) announced on October 12, 2026, that new and long-term molgramostim data will be presented at CHEST 2026 from October 18 to October 21. According to Business Wire, the company will show an encore oral presentation from the Phase 3 IMPALA-2 trial and a poster from the Phase 2/3 IMPALA trial.

CHEST presentations set the timetable

The oral presentation is scheduled for October 20, 2026, and covers long-term efficacy and safety during the IMPALA-2 open-label treatment period. A poster on treatment effects in patients with mild diffusion impairment is scheduled for October 21, 2026, giving the company two data points during the medical meeting.

The chronology shows how the regulatory story has developed. On April 15, 2026, Savara said the FDA had extended its review of the molgramostim application toward a November 22 action date, according to Yahoo Finance. On August 11, 2026, second-quarter earnings per share were USD -0.16 versus USD -0.14 expected. The October 12, 2026 CHEST announcement is the latest event.

What does November 22 mean for valuation?

The FDA decision remains the clearest numerical test for Savara's single-product strategy. Yahoo Finance reported that JPMorgan began coverage on October 7, 2026, with an Overweight rating and a USD 12.00 price target, compared with a USD 4.88 close cited in the report. The same report said Savara's market capitalization was supported by expectations for a potential launch, while wider projected losses increased the risk around that valuation.

Next dates for investors

The next two dated events are the October 20, 2026 oral presentation and the estimated November 11, 2026 third-quarter results. MarketBeat lists the November report after the market close and estimates consensus earnings per share of USD -0.1633 for the quarter.

Stock valuation and company profile

Savara is a clinical-stage biotechnology company focused on rare respiratory diseases, with molgramostim as its lead program. Its market capitalization was USD 914.3 million as of October 16, 2026, while the 52-week range was USD 3.60 to USD 7.01. The company is listed on Nasdaq under SVRA.

The last available Frankfurt quote stood at EUR 3.94 on October 16, 2026. The euro price is a dated German-market reference rather than a live October 18 quotation.